AstraZeneca DESTINY-PanTumor02 (Solid Tumors)

What is the Purpose of this Study?

If you choose to join this study you will:
-Have an infusion of the study drug (trastuzumab deruxtecan) once every 3 weeks
-Provide old tumor tissue
-Have an eye exam
-Have physical exams, blood and urine tests
-Have imaging scans (CT and/or MRI)
What is the Condition Being Studied?
Advanced solid tumors that express HER2

Who Can Participate in this Study?

Adults with the following advanced solid tumors that express HER2

-Biliary tract cancer

-Bladder cancer

-Cervical cancer

-Endometrial cancer

-Ovarian cancer

-Rare tumors (excluding breast, non-small cell lung cancer, gastric cancer, and colorectal cancer

Age Group
Adults
Participating Institutions

What is Involved?

We are doing this research study to understand the effectiveness and safety of trastuzumab deruxtecan (T-DXd) on select HER2-expressing tumors (tumors that have a specific protein on their surface).

Study Details

Full Title
A Phase II, Multicenter, Open-label Study to Evaluate the Efficacy and Safety of Trastuzumab Deruxtecan (T-DXd, DS-8201a) for the Treatment of Selected HER2-expressing Tumors (DESTINY-PanTumor02)
Principal Investigator

Contacts
Phase I Clinical Trials Office DCI Clinical Research Team
Protocol Number
IRB:
PRO00107117

NCT:
NCT04482309
ClinicalTrials.gov
View on ClinicalTrials.gov